OTC triptans market research

Euromonitor has the world’s most comprehensive research on the OTC triptans category within the consumer health industry. We monitor and analyse industry trends around the world, including in-depth data on market share and market size – from the “big picture” qualitative analysis; down to specific category data.

Euromonitor data and market analysis cultivates your organization’s awareness of the OTC triptans market and the greater competitive environment, ensuring accurate and focused strategies for your business.

A resource for your entire organization, Euromonitor market research supports every level of business, assisting in strategic development, marketing, mergers and acquisitions, and brand management.

Our OTC triptans market research answer questions such as:

What is the market size of OTC triptans?
What are the major brands in OTC triptans?
What are the major brands in OTC triptans?
Are OTC triptans legally available?
How many generations of triptans are sold?

Filter Results

Total: (7)

by Product Type
- Reports (7)
  - Country Reports (7)
by Geography
by Date
- Last Year (7)

Country Report

OTC Triptans in Germany

2011 saw the introduction of a second product in the category in Germany; Dolortriptan, with the active ingredient almotriptan, was introduced by Johnson & Johnson GmbH. This launch and the continued growth of Formigran (GlaxoSmithKline GmbH & Co KG)...

Jul 2012 | US$900| Add to cart | View details ›

Country Report

OTC Triptans in Sweden

The growing self-medication trend was a key driver of sales in 2011. OTC triptans products are most likely to be purchased by consumers who believe they are suffering from a migraine but who have not been diagnosed by a medical professional.

Jun 2012 | US$900| Add to cart | View details ›

Country Report

OTC Triptans in the United Kingdom

In 2011, sales of triptans were worth £6 million. Rising anxiety and stress levels caused by concerns over job and financial security are causing a rise in migraines and headaches in general. It is important for a pharmacist to distinguish between a ...

Jun 2012 | US$900| Add to cart | View details ›

Country Report

OTC Triptans in the Czech Republic

OTC triptans was only available via prescription in the Czech Republic in 2011 and there are no indications that such products will be made available OTC in the foreseeable future.

Apr 2012 | US$900| Add to cart | View details ›

Country Report

OTC Triptans in Russia

In 2011 all drugs classified as triptans remained Rx in Russia. Doctors can prescribe triptans to patients suffering from migraines if this diagnosis is approved. A switch to OTC is not expected, due to the specifics of the product and the known love...

Mar 2012 | US$900| Add to cart | View details ›

Country Report

OTC Triptans in Estonia

Triptans are only available as Rx medicine in Estonia. Triptans which are prescribed include Zolmitriptan Actavis 5mg (produced by Actavis Ltd), Imigran (produced by GlaxoSmithKline), Sumatriptan Sandoz (produced by Sandoz) and Cinie (produced by ...

Mar 2012 | US$900| Add to cart | View details ›

Country Report

OTC Triptans in New Zealand

In June 2006, sumatriptan was reclassified from a prescription medicine to a restricted medicine (sold by a pharmacist in a pharmacy). This reclassification applied to packs of no more than two 50mg tablets. As a result of this reclassification, ...

Mar 2012 | US$900| Add to cart | View details ›